Biopharmaceuticals promise to boost downstream processing in Asia

Global contract manufacturing organizations (CMOs) are set to steadily become more and more popular, as Western pharmaceutical companies outsource production to Asian countries in a bid to cut costs, forecasts a new report by health care experts GBI Research, which notes that the overall cost of drug manufacturing is up to 50% cheaper in India than in Western countries, which is pushing Big Pharma abroad.

Major CMOs offer upstream and downstream manufacturing functions equally; and, in addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging and even marketing. According to the industry experts, manufacturing functions dominate almost 60% of the CMO market, with downstream processes accounting for 50% of the manufacturing process.

15% CAGR forecast